TGFB1 and neoplasm: PI3K/AKT pathway inhibitors, such as pilaralisib (XL-147), BEZ235, and buparlisib; NF-κB pathway inhibitors, such as bortezomib and eupatilin; as well as TGF-β inhibitors and antiangiogenic agents (cetuximab) have been associated with varying degrees of tumor inhibition and stemness loss in basic and clinical studies [178–180].